Evidence map›Paper›PMID 27185213›Full record

ArticleCancer medicine2016

Reduction in squamous cell carcinomas in mouse skin by dietary zinc supplementation.

Jin Sun, Rulong Shen, Morgan S Schrock, James Liu, Xueliang Pan, Donald Quimby, Nicola Zanesi, Teresa Druck, Louise Y Fong, Kay Huebner

Open access · goldAbstract read
In one paragraph

Article in Cancer medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 12 citations in OpenAlex.

  1. Zinc treatment reverses and anti-Zn-regulated miRs suppress esophageal carcinomas in vivo.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  2. Serum Levels of Zinc, Copper and Ferritin in Patients with Salivary Gland TumorsAsian Pacific journal of cancer prevention : APJCP · 2019
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Jin SunDepartment of Molecular Virology, Immunology and Medical Genetics, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Rulong ShenDepartment of Pathology, College of Medicine, Columbus, Ohio.
Morgan S SchrockDepartment of Molecular Virology, Immunology and Medical Genetics, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
James LiuDepartment of Molecular Virology, Immunology and Medical Genetics, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Xueliang PanDepartment of Biomedical Informatics, Center for Biostatistics, The Ohio State University, Columbus, Ohio.
Donald QuimbyDepartment of Molecular Virology, Immunology and Medical Genetics, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Nicola ZanesiDepartment of Molecular Virology, Immunology and Medical Genetics, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Teresa DruckDepartment of Molecular Virology, Immunology and Medical Genetics, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Louise Y FongDepartment of Pathology, Anatomy & Cell Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania.
Kay HuebnerDepartment of Molecular Virology, Immunology and Medical Genetics, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Cancer Genetics (United States) · USThe Ohio State University · USColumbus State Community College · USThomas Jefferson University · US

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Jennifer A. Woyach · 1985 to 2026
$132.3M
Chemoprevention of upper aerodigestive tract cancer by dietary zincR01CA118560 · NCI · THOMAS JEFFERSON UNIVERSITY · PI FONG, LOUISE Y.Y. · 2006 to 2017
$2.7M
Fhit modulation of cell cycle progression and DNA damage responseR01CA132453 · NCI · OHIO STATE UNIVERSITY · PI HUEBNER, KAY · 2007 to 2010
$1.3M
FHIT Gene Therapy in Cancer Prevention and TreatmentR01CA115965 · NCI · OHIO STATE UNIVERSITY · PI CROCE, CARLO M · 2007 to 2011
$1.1M
NCI NIH HHS P30 CA016058NCI NIH HHS R01 CA115965NCI NIH HHS R01 CA118560NCI NIH HHS R01 CA132453
6 · The paper itself

Abstract

Inadequate dietary Zn consumption increases susceptibility to esophageal and other cancers in humans and model organisms. Since Zn supplementation can prevent cancers in rodent squamous cell carcinoma (SCC) models, we were interested in determining if it could have a preventive effect in a rodent skin cancer model, as a preclinical basis for considering a role for Zn in prevention of human nonmelanoma skin cancers, the most frequent cancers in humans. We used the 7,12-dimethyl benzanthracene carcinogen/phorbol myristate acetate tumor promoter treatment method to induce skin tumors in Zn-sufficient wild-type and Fhit (human or mouse protein) knockout mice. Fhit protein expression is lost in >50% of human cancers, including skin SCCs, and Fhit-deficient mice show increased sensitivity to carcinogen induction of tumors. We hypothesized that: (1) the skin cancer burdens would be reduced by Zn supplementation; (2) Fhit(-/-) (Fhit, murine fragile histidine triad gene) mice would show increased susceptibility to skin tumor induction versus wild-type mice. 30 weeks after initiating treatment, the tumor burden was increased ~2-fold in Fhit(-/-) versus wild-type mice (16.2 versus 7.6 tumors, P < 0.001); Zn supplementation significantly reduced tumor burdens in Fhit(-/-) mice (males and females combined, 16.2 unsupplemented versus 10.3 supplemented, P = 0.001). Most importantly, the SCC burden was reduced after Zn supplementation in both strains and genders of mice, most significantly in the wild-type males (P = 0.035). Although the mechanism(s) of action of Zn supplementation in skin tumor prevention is not known in detail, the Zn-supplemented tumors showed evidence of reduced DNA damage and some cohorts showed reduced inflammation scores. The results suggest that mild Zn supplementation should be tested for prevention of skin cancer in high-risk human cohorts.

Indexed as

Dietary SupplementsAcid Anhydride HydrolasesAnimalsBis(5'-adenosyl)triphosphataseCarcinoma, Squamous CellDisease Models, AnimalDNA DamageFemaleInflammationMaleMiceMice, KnockoutNeoplasm ProteinsSkinSkin NeoplasmsTumor BurdenAcid Anhydride HydrolasesBis(5'-adenosyl)triphosphataseNeoplasm ProteinsZincDMBA-induced skin tumorsFhit knockout micetumor preventiontumor suppressor-deficient micezinc supplementation

Identifiers

PMID27185213
PMCPMC4873604
OpenAlexW2405807402

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.